Hepatitis B virus reactivation in a chronic myeloid leukemia patient treated with imatinib mesylate.
- Author:
Ya-Dan WANG
1
;
Guo-Hui CUI
;
Mian LI
;
Bhuveshwarnath GOWREA
;
Jia XIA
;
Yu HU
Author Information
1. Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, China.
- Publication Type:Case Reports
- MeSH:
Adult;
Benzamides;
Hepatitis B virus;
pathogenicity;
Humans;
Imatinib Mesylate;
Leukemia, Myelogenous, Chronic, BCR-ABL Positive;
drug therapy;
virology;
Male;
Piperazines;
therapeutic use;
Pyrimidines;
therapeutic use;
Virus Replication;
drug effects
- From:
Chinese Medical Journal
2012;125(14):2636-2637
- CountryChina
- Language:English
-
Abstract:
Imatinib mesylate is a molecular targeted agent for treating chronic myeloid leukemia (CML) and gastrointestinal stromal tumor. Although imatinib mesylate is not regarded as an immunosuppressive agent, few studies have also shown that it may impair immune response. In this report, we present a case of transient hepatitis B virus (HBV) reactivation during imatinib mesylate treatment for CML.
